Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Business Wire
– Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia –– Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression –– Key learnings from ALTO-100 Phase 2b MDD trial including clinically meaningful effect observed in a pre-specified secondary analysis and evidence of stratification using the pre-specified enrichment biomarker in patients with confirmed drug compliance –– Strong cash position of approximately $182 million is expected to fund planned operations into 2027, and through at least four additional clinical study readouts – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the third
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- The Schall Law Firm Wants Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud Accesswire
- Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law FirmAccesswire
- The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities FraudAccesswire
- Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Encouraged To Contact The Schall Law FirmAccesswire
- The Schall Law Firm Wants Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Fraud Accesswire
ANRO
Earnings
- 11/12/24 - Beat
ANRO
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- ANRO's page on the SEC website